SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014767
Filing Date
2024-11-07
Accepted
2024-11-07 08:35:30
Documents
45
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20240930x10q.htm   iXBRL 10-Q 1558698
2 EX-10.1 apre-20240930xex10d1.htm EX-10.1 82928
3 EX-31.1 apre-20240930xex31d1.htm EX-31.1 10482
4 EX-31.2 apre-20240930xex31d2.htm EX-31.2 10768
5 EX-32.1 apre-20240930xex32d1.htm EX-32.1 6903
6 EX-32.2 apre-20240930xex32d2.htm EX-32.2 6948
  Complete submission text file 0001558370-24-014767.txt   4197088

Data Files

Seq Description Document Type Size
7 EX-101.SCH apre-20240930.xsd EX-101.SCH 25200
8 EX-101.CAL apre-20240930_cal.xml EX-101.CAL 28605
9 EX-101.DEF apre-20240930_def.xml EX-101.DEF 97056
10 EX-101.LAB apre-20240930_lab.xml EX-101.LAB 233421
11 EX-101.PRE apre-20240930_pre.xml EX-101.PRE 160484
48 EXTRACTED XBRL INSTANCE DOCUMENT apre-20240930x10q_htm.xml XML 328598
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 617-463-9385
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 241433375
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)